Compare Stocks: LIMN, BCDA, TPST, and AKTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$10.70 +18.8%	$9.61	$3.02 ▼ $49.60	$20.83M	1.4	55,985 shs	168,209 shs
BCDA BioCardia	$1.15 -1.7%	$0.98	$0.75 ▼ $2.29	$17.41M	0.48	265,131 shs	158,989 shs
LIMN Liminatus Pharma	$4.23 -3.9%	$5.70	$4.23 ▼ $154.50	$4.28M	5.35	655,043 shs	38,621 shs
TPST Tempest Therapeutics	$1.06 -1.9%	$1.03	$0.84 ▼ $12.23	$17.53M	-1.72	286,127 shs	62,265 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	+36.31%	+33.75%	-34.88%	-68.38%
BCDA BioCardia	0.00%	+13.86%	+49.14%	+23.66%	-40.72%
LIMN Liminatus Pharma	0.00%	-18.02%	-17.14%	-48.41%	-97.20%
TPST Tempest Therapeutics	0.00%	+1.92%	+22.73%	-30.72%	-90.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKTX Akari Therapeutics	$10.70 +18.8%	$9.61	$3.02 ▼ $49.60	$20.83M	1.4	55,985 shs	168,209 shs
BCDA BioCardia	$1.15 -1.7%	$0.98	$0.75 ▼ $2.29	$17.41M	0.48	265,131 shs	158,989 shs
LIMN Liminatus Pharma	$4.23 -3.9%	$5.70	$4.23 ▼ $154.50	$4.28M	5.35	655,043 shs	38,621 shs
TPST Tempest Therapeutics	$1.06 -1.9%	$1.03	$0.84 ▼ $12.23	$17.53M	-1.72	286,127 shs	62,265 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKTX Akari Therapeutics	0.00%	+36.31%	+33.75%	-34.88%	-68.38%
BCDA BioCardia	0.00%	+13.86%	+49.14%	+23.66%	-40.72%
LIMN Liminatus Pharma	0.00%	-18.02%	-17.14%	-48.41%	-97.20%
TPST Tempest Therapeutics	0.00%	+1.92%	+22.73%	-30.72%	-90.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKTX Akari Therapeutics	2.50	Moderate Buy	$32.33	202.18% Upside
BCDA BioCardia	2.00	Hold	$25.00	2,073.91% Upside
LIMN Liminatus Pharma	1.00	Sell	N/A	N/A
TPST Tempest Therapeutics	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest LIMN, BCDA, TPST, and AKTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/20/2026	AKTX Akari Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$30.00
7/17/2026	BCDA BioCardia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	TPST Tempest Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/13/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/6/2026	AKTX Akari Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/24/2026	LIMN Liminatus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/9/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	$9.55 per share	N/A
BCDA BioCardia	N/A	N/A	N/A	N/A	$0.18 per share	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	$0.30 per share	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	($0.07) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKTX Akari Therapeutics	-$17.30M	N/A	N/A	N/A	N/A	N/A	-147.45%	-74.70%	N/A
BCDA BioCardia	-$8.23M	-$0.64	N/A	N/A	N/A	N/A	-569.36%	-183.15%	11/11/2026 (Estimated)
LIMN Liminatus Pharma	-$10.21M	-$23.50	N/A	N/A	N/A	N/A	N/A	-256.58%	N/A
TPST Tempest Therapeutics	-$26.26M	-$4.28	N/A	N/A	N/A	N/A	-576.56%	-134.99%	11/4/2026 (Estimated)

Latest LIMN, BCDA, TPST, and AKTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LIMN Liminatus Pharma	N/A	-$1.50	N/A	-$0.03	N/A	N/A
8/13/2026	Q2 2026	TPST Tempest Therapeutics	-$0.30	-$0.34	-$0.04	-$0.34	N/A	N/A
8/12/2026	Q2 2026	BCDA BioCardia	-$0.18	-$0.13	+$0.05	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKTX Akari Therapeutics	N/A	N/A	N/A	N/A	N/A
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
LIMN Liminatus Pharma	N/A	N/A	N/A	N/A	N/A
TPST Tempest Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKTX Akari Therapeutics	N/A	0.60	0.60
BCDA BioCardia	N/A	2.09	2.09
LIMN Liminatus Pharma	N/A	1.12	1.12
TPST Tempest Therapeutics	N/A	0.38	0.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKTX Akari Therapeutics	5.06%
BCDA BioCardia	20.57%
LIMN Liminatus Pharma	N/A
TPST Tempest Therapeutics	22.52%

Insider Ownership

Company	Insider Ownership
AKTX Akari Therapeutics	32.20%
BCDA BioCardia	17.40%
LIMN Liminatus Pharma	19.40%
TPST Tempest Therapeutics	36.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKTX Akari Therapeutics	9	1.95 million	1.32 million	Not Optionable
BCDA BioCardia	40	15.14 million	12.51 million	Optionable
LIMN Liminatus Pharma	N/A	1.01 million	816,000	N/A
TPST Tempest Therapeutics	20	16.54 million	10.55 million	No Data

LIMN, BCDA, TPST, and AKTX Headlines

Recent News About These Companies

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors

August 13, 2026 | quiverquant.comQ

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update

August 13, 2026 | globenewswire.com

Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | finanznachrichten.de

Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases

July 21, 2026 | quiverquant.comQ

Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T

July 21, 2026 | globenewswire.com

Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial

July 15, 2026 | quiverquant.comQ

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026

July 15, 2026 | globenewswire.com

Tempest Therapeutics, Inc. Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026 | quiverquant.comQ

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

June 4, 2026 | globenewswire.com

Tempest Therapeutics Announces Resignation of Board Director

May 29, 2026 | tipranks.com

Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants

May 29, 2026 | quiverquant.comQ

Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds

May 29, 2026 | globenewswire.com

Tempest Therapeutics Announces Multiple Board Director Resignations

May 22, 2026 | tipranks.com

Tempest Therapeutics: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 15, 2026 | finanznachrichten.de

Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

May 14, 2026 | globenewswire.com

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

May 6, 2026 | globenewswire.com

Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting

April 29, 2026 | globenewswire.com

Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T

April 22, 2026 | globenewswire.com

Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts

April 14, 2026 | globenewswire.com

New Strong Buy Stocks for April 10th

April 10, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, BCDA, TPST, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

$10.70 +1.69 (+18.76%)

As of 08/28/2026 04:00 PM Eastern

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

BioCardia NASDAQ:BCDA

$1.15 -0.02 (-1.71%)

As of 08/28/2026 04:00 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Liminatus Pharma NASDAQ:LIMN

$4.23 -0.17 (-3.86%)

As of 08/28/2026 04:00 PM Eastern

Liminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.

Tempest Therapeutics NASDAQ:TPST

$1.06 -0.02 (-1.85%)

As of 08/28/2026 04:00 PM Eastern

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIMN, BCDA, TPST, and AKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIMN, BCDA, TPST, and AKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIMN, BCDA, TPST, and AKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, BCDA, TPST, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

BioCardia NASDAQ:BCDA

Liminatus Pharma NASDAQ:LIMN

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LIMN, BCDA, TPST, and AKTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LIMN, BCDA, TPST, and AKTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LIMN, BCDA, TPST, and AKTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN, BCDA, TPST, and AKTX Company Descriptions

Akari Therapeutics NASDAQ:AKTX

BioCardia NASDAQ:BCDA

Liminatus Pharma NASDAQ:LIMN

Tempest Therapeutics NASDAQ:TPST

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools